The shares are currently held by Claris Lifesciences , a pharmaceutical company based in India.
Based in Japan, the acquirer company manufactures and distributes industrial and pharmaceutical chemicals.
The purchase consideration for the acquisition is $20m.
German biopharmaceutical company Sygnis has agreed to acquire UK-based Innova Biosciences.
The purchase consideration for the acquisition will include €8m ($8.79m) in cash and up to 3.5 million in shares.